← Human Trials & Peer-Reviewed Studies
Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder.
Plain-language guide to PMID 18022679 (2008): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 18022679
- Journal
- Pharmacology, biochemistry, and behavior
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Potter AS et al. (2 authors)
- DOI
- 10.1016/j.pbb.2007.09.014
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
The strong association between ADHD and cigarette smoking and the known effects of nicotine on cognition has lead to interest in the role of cholinergic function in ADHD cognitive deficits.
This study examined acute nicotine in young adults with ADHD-Combined type on cognitive domains including behavioral inhibition, delay aversion, and recognition memory.
Who Took Part
PubMed indexes the participants as adults, both men and women.
Three subjects experienced side effects and their data was excluded from analysis of cognitive measures.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The comparison arm used a placebo, so changes seen with Therapeutic nicotine (patch, non-peptide) could be set against what happens without it.
Cognitive tasks included the Stop Signal Task, Choice Delay task, and the High-Low Imagery Task (a verbal recognition memory task).
What Was Measured
PubMed files the paper under topics including Administration, Cutaneous, Affect, Attention Deficit Disorder with Hyperactivity, Behavior, Choice Behavior, Cognition and Data Interpretation, Statistical.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2008 (Pharmacology, biochemistry, and behavior), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.